Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section
Research
Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
I-Ching Sam*1, Francis Drobniewski*
, Philip More*, Melanie Kemp*, and Timothy Brown*
, Philip More*, Melanie Kemp*, and Timothy Brown*
Table 3
Final culture identification results for all specimens*
| Result | Primary specimens, no. (%) | Isolates, no. (%) | Total, no. (%) |
|---|---|---|---|
| MTBC | |||
| Rifampin sensitive† | 892 (94.9) | 214 (90.9) | 1,106 (93.9) |
| Rifampin resistant only† | 9 (1.0) | 3 (1.3) | 12 (1.0) |
| MDRTB† | 37 (3.9) | 20 (8.4) | 57 (4.8) |
| Susceptibilities not determined† | 2 (0.2) | 1 (0.4) | 3 (0.3) |
| Total MTBC | 940 (47.1) | 238 (82.1) | 1,178 (51.5) |
| NTM | 181 (9.1) | 42 (14.5) | 223 (9.8) |
| Contaminated | 22 (1.1) | 8 (2.8) | 30‡ (1.3) |
| Culture not done | 5 (0.3) | 1 (0.3) | 6‡ (0.3) |
| No mycobacterial spp. | 849 (42.5) | 1 (0.3) | 850 (37.2) |
| Total | 1,997 | 290 | 2,287 |
*MTBC, Mycobacterium tuberculosis complex; MDRTB, multidrug-resistant tuberculosis; NTM, nontuberculous mycobacteria.
†Percentages of total MTBC cultures.
‡These 36 (1.6%) cases without definitive culture results were excluded from analyses of assay performance.
1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia
Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.